ライフサイエンスコーパス: odds ratio

1 able ordinal logistic regression to estimate odds ratios.

2 We used a random-effects model to pool odds ratios.

3 ients with no history of glucocorticoid use (odds ratio 0.47, 95% CI 0.22-1.00; p=0.0501).

4 ratio 0.82, P = 0.001) and general surgeons (odds ratio 0.65, P = 0.002).

5 mortality only among early-career surgeons (odds ratio 0.82, P = 0.001) and general surgeons (odds r

6 nce = 4.1% [95% CI, -1.4% to 9.6%]; adjusted odds ratio = 0.61 [95% CI, 0.31 to 1.21]; P = .16).

7 66) of in-hospital mortality and lower odds (odds ratio = 0.8; 95% CI = 0.72-0.9) of being discharged

8 s in 2 independent cohorts (combined cohort: odds ratio, 0.06; 95% CI, 0.02-0.22; P = 2.17 x 10-7).

9 ated with a significant risk of FMT failure (odds ratio, 0.15; 95% confidence interval, .007-.40).

10 nt shows a trend toward a protective effect (odds ratio, 0.16; 95% CI, 0.0-1.3; P = .08).

11 ssociated with reduced mortality (P = 0.005; odds ratio, 0.204; 95% confidence interval, 0.066-0.624)

12 ssion compared to no NAI treatment (adjusted odds ratio, 0.24; 95% confidence interval, 0.20-0.30).

13 39) and a reduced risk in adjusted analyses (odds ratio, 0.41; 95% CI, 0.171 to 0.986; P = .046).

14 ignificant decrease in the risk of delirium (odds ratio, 0.47; 95% CI, 0.38-0.56).

15 y associated with lower odds of mammography (odds ratio, 0.4; 95% CI, 0.3 to 0.8 for </= 5-year life

16 patients treated with second-generation DES (odds ratio, 0.51; 95% confidence interval, 0.38-0.68; P<

17 ho performed farm activities while pregnant (odds ratio, 0.60; 95% CI, 0.48-0.74) and remained signif

18 ,507; p = 0.08; I, 53%; random effect model: odds ratio, 0.63; 95% CI, 0.37-1.06).

19 nt) versus 137 (0.99+/-1.79 points/patient) (odds ratio, 0.64; confidence interval, 0.39-1.03; P=0.06

20 e of asthma between 8 and 16 years (adjusted odds ratio, 0.67; 95% CI, 0.47-0.94).

21 d risk of hepatic steatosis in participants (odds ratio, 0.69; 95% CI= 0.55-0.93; P value: 2.7 x 10(-

22 wer risk of death and myocardial infarction (odds ratio, 0.71; 95% confidence interval, 0.55-0.91).

23 wer risk of death and myocardial infarction (odds ratio, 0.76; 95% confidence interval, 0.61-0.94; P=

24 lacebo (145 [31.7%] vs 174 [37.6%]; adjusted odds ratio, 0.78; 95% CI, 0.59-1.02; P = .07).

25 compared to 213 (39%) in the control group (odds ratio, 0.81; 95% confidence interval, 0.64-1.04; P

26 2,112; p = 0.29; I, 25%; fixed effect model: odds ratio, 0.83; 95% CI, 0.58-1.17) or rate of intubati

27 ts were not associated with incident stroke (odds ratio, 0.84; 95% CI, 0.48-1.47 in blacks and odds r

28 roups (49.3% vs. 46.3%, adjunct vs. control; odds ratio, 0.89; 95% confidence interval, 0.46-1.74; P

29 77-1.13; I = 0.0%) or observational studies (odds ratio, 0.90; 95% CI, 0.54-1.51; I = 76.1%).

30 95% confidence interval [CI], -2.93 to 0.72; odds ratio, 0.90; 95% CI, 0.76 to 1.07; P<0.001 for noni

31 e an increased odds of death within 28 days (odds ratio, 0.94; 95% CI, .67-1.32).

32 MI performance measures and MI-ERR (adjusted odds ratio, 0.94; 95% CI, 0.81-1.08, per 0.1-unit increa

33 isk of primary ischemic outcome at 180 days (odds ratio, 0.96; 95% confidence interval, 0.75-1.23), w

34 ociated with a 34% reduction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98;

35 idence interval: 0.84-1.37) and VNTR 7 DRD4 (odds ratio: 0.68; confidence interval: 0.47-1.00).

36 nce interval: 1.16-2.37) and VNTR 10 SLC6A3 (odds ratio: 0.74; confidence interval: 0.60-0.90), where

37 statistically significant: rs1947274 LPHN3 (odds ratio: 0.95; confidence interval: 0.71-1.26), rs566

38 ctor for indication for step-down treatment (Odds ratio; 0.19).

39 vs 5.2 days; P = 0.015), more complications (odds ratio 1.36; 95% CI 1.04-1.78; adjusted rates 20% vs

40 frican ancestry-specific variant, rs1049549 (odds ratio 1.49 [95% CI 1.27-1.75]).

41 ere more likely to experience complications (odds ratio 1.51, P = 0.002) and longer hospital stays (+

42 (RPE) hemorrhage related to neovascular AMD (odds ratio 1.55 [95% confidence interval 1.31-1.84], P =

43 s 20% vs 16%; P = 0.023), more readmissions (odds ratio 1.57; 95% CI 1.08-2.29; adjusted rates 10% vs

44 2.62) for Crohn's disease and 1.3% and 0.7% (odds ratio 1.75; 1.44-2.13) for ulcerative colitis.

45 cant difference in mortality (n = 5 studies; odds ratio = 1.07; 95% CI, 0.95-1.21; p = 0.27; I = 0%),

46 tly associated with a higher risk of anemia (odds ratio = 1.14; 95% confidence interval: 1.01-1.28) a

47 escents whose parents separated (for ALSPAC, odds ratio = 1.46; for Pelotas Birth Cohort, odds ratio

48 d good predictive validity with higher odds (odds ratio = 1.47; 95% CI = 1.30-1.66) of in-hospital mo

49 y differed significantly between the groups, Odds ratio = 1.69.

50 odds ratio = 1.46; for Pelotas Birth Cohort, odds ratio = 1.98).

51 e risk of a patient having any complication (odds ratio, 1.0063; 95% CI, 1.0004-1.0123; P = .03), any

52 -1.0186; P = .01), any medical complication (odds ratio, 1.0079; 95% CI, 1.0009-1.0148; P = .03), and

53 0009-1.0148; P = .03), and being readmitted (odds ratio, 1.0088, 95% CI, 1.0024-1.0151; P = .007).

54 completion of a bolus of intravenous fluids (odds ratio, 1.01 per hour; 95% CI, 0.99 to 1.02; P=0.21)

55 1.0123; P = .03), any surgical complication (odds ratio, 1.0104; 95% CI, 1.0022-1.0186; P = .01), any

56 r time to the administration of antibiotics (odds ratio, 1.04 per hour; 95% CI, 1.03 to 1.06; P<0.001

57 higher risk-adjusted in-hospital mortality (odds ratio, 1.04 per hour; 95% confidence interval [CI],

58 rongly associated with lacunar subtype only (odds ratio, 1.05, P = 0.0012).

59 ratio, 0.84; 95% CI, 0.48-1.47 in blacks and odds ratio, 1.06; 95% CI, 0.80-1.41 in whites).

60 95% CI, 1.02-1.06; p < 0.001) and mortality (odds ratio, 1.06; 95% CI, 1.04-1.08; p < 0.001).

61 associated with increased odds of response (odds ratio, 1.08; 95% confidence interval [CI]: 1.00, 1.

62 for failure of standard retrieval technique (odds ratio, 1.08; 95% confidence interval, 1.05-1.10; P<

63 The odds of recurrence (odds ratio, 1.13; 95% CI, .94-1.36) were similar among p

64 the laboratory arm and 79.5% in the POC arm (odds ratio, 1.13; 95% confidence interval, 0.51-2.53; P

65 patients had a 15% higher hospital survival (odds ratio, 1.15; 95% CI, 1.09-1.22; p < 0.001).

66 lysis, no difference in mortality was found (odds ratio, 1.16; 95% CI, 0.89-1.50).

67 ociated with increased mortality (P = 0.003; odds ratio, 1.254; 95% confidence interval, 1.078-1.457)

68 ated polyposis and multiple serrated polyps (odds ratio, 1.35; 95% confidence interval [CI], 0.64-2.8

69 oma vs those with ductal carcinoma (adjusted odds ratio, 1.44; 95% CI 1.06-1.95; P = .02).

70 versus 38.0% (155/408) of transfer patients (odds ratio, 1.47; 95% confidence interval, 1.13-1.92; P=

71 highest category versus <limit of detection; odds ratio, 1.50; 95% confidence interval, 1.09-2.07), b

72 ation than white subjects in the ICS+ group (odds ratio, 1.58; 95% CI, 1.01-2.48; P = .046) but not i

73 0.001), and low institutional volume of BAV (odds ratio, 1.58; 95% confidence interval, 1.06-2.37; P=

74 ive outcome in propensity-adjusted analysis (odds ratio, 1.61; 95% confidence interval [CI], 1.13-2.2

75 ssociated with increased hospital mortality (odds ratio, 1.63; 95% CI, 1.01-2.63) and longer length o

76 over conventional treatment (adjusted common odds ratio, 1.68; 95% confidence interval [CI], 1.15 to

77 ted risk of death/MI was higher among women (odds ratio, 1.6; 95% CI, 1.1-2.4) and minorities (odds r

78 ome quartile (mean income, $30534) (adjusted odds ratio, 1.74; 95% CI, 1.50-2.03).

79 after adjustment for 16 covariates (adjusted odds ratio, 1.77; 95% CI, 1.17 to 2.68); death occurred

80 greater risk-adjusted in-hospital mortality (odds ratio, 1.89 [95% CI, 1.79-2.00]).

81 f 153 [29.4%] vs 38 of 201 [18.9%]; adjusted odds ratio, 1.8; 95% CI, 1.5-2.2).

82 = 0.27) and treatment response (beta = 0.53; odds ratio, 1.95; 95% CI, 1.52-2.50; number needed to tr

83 s usual, 31 of 116 [26.7%]) after 12 months (odds ratio, 1.97; 95% CI, 0.99 to 3.94; P = .03).

84 ratio, 1.6; 95% CI, 1.1-2.4) and minorities (odds ratio, 1.9; 95% CI, 1.2-2.8) compared with white me

85 ng increased reliance on gait aids (adjusted odds ratio, 1.9; 95% CI, 1.4-2.6); no functional status

86 ed with a 5% increased odds of DGF (adjusted odds ratio: 1.05, 95% confidence interval [CI], 1.02-1.0

87 dence interval: 0.71-1.26), rs5661665 LPHN3 (odds ratio: 1.07; confidence interval: 0.84-1.37) and VN

88 variable number tandem repeat (VNTR) 4 DRD4 (odds ratio: 1.66; confidence interval: 1.16-2.37) and VN

89 otide polymorphisms (SNPs) rs1800544 ADRA2A (odds ratio: 1.69; confidence interval: 1.12-2.55), rs468

90 fidence interval: 1.04-1.87), rs5569 SLC6A2 (odds ratio: 1.73; confidence interval: 1.26-2.37) and rs

91 an-Failure Assessment score greater than 10 (odds ratio, 12.9 [95% CI, 1.2-140]; p = 0.04) and cumula

92 e history was the strongest predictor of OD (odds ratio = 14.8; 95% confidence interval: 12.7-17.2).

93 C ratio at 7 years was associated with ACOS (odds ratio, 16.3; 95% confidence interval, 4.7-55.9) and

94 ed fluid-therapy volume greater than 10.7 L (odds ratio, 16.8 [1.6-180]; p = 0.02) as independent pre

95 dds of lateral precordial T-wave inversions (odds ratio, 18.4; 95% confidence interval, 2.92-116.18;

96 (26%) of 246 in the standard-of-care group (odds ratio 19.94, 95% CI 3.86-103.04, p=0.0004).

97 S vs. general population) was 0.8% and 0.3% (odds ratio 2.04; 1.59-2.62) for Crohn's disease and 1.3%

98 isting increased 117% over 9 years (adjusted odds ratio 2.17, 95% confidence interval, 1.82-2.58).

99 s to experience postoperative complications (odds ratio 2.2, 95% confidence interval 1.6-3.0).

100 d with four (4%) of 105 controls (unadjusted odds ratio 2.4, 95% CI 0.8-7.3).

101 red to 25.8% (95% CI, 24.5-27.1%) and median odds ratio 2.8 for diagnosis.

102 ssociated with the later development of JIA (odds ratio = 2.4, 95% confidence interval: 1.6, 3.6).

103 s 43% with cannabidiol and 27% with placebo (odds ratio, 2.00; 95% CI, 0.93 to 4.30; P=0.08).

104 ine, the odds of successful therapy doubled (odds ratio, 2.154; 95% CI, 1.173-3.955).

105 was associated with a larger atheroma size (odds ratio, 2.15; 95% confidence interval, 1.06-4.76; P=

106 re worker activities (touching the bed rail [odds ratio, 2.19; 95% CI, 1.00-4.82], performing a wound

107 interval, 2.25-5.36; P<0.001), coagulopathy (odds ratio, 2.19; 95% confidence interval, 1.51-3.18; P<

108 remained independently associated with STDR (odds ratio, 2.3; 95% confidence interval, 1.1-4.9; P = 0

109 a significant higher risk of dying (adjusted odds ratio, 2.59; 95% CI, 1.66-4.03).

110 djusted risk of MI was higher in minorities (odds ratio, 2.6; 95% CI, 1.4-4.8).

111 creased risk for delirium the following day (odds ratio, 2.83 [1.27-6.59]; p = 0.02).

112 gone a previous clinical breast examination (odds ratio, 2.92; 95% CI, 1.30-6.60; P = .01).

113 he ipilimumab arm had an objective response (odds ratio, 2.9; 95% CI, 1.5 to 5.5; P = .002).

114 dent CMR predictor of the combined endpoint (odds ratio: 2.73; 95% confidence interval: 1.2 to 5.9; p

115 interval: 1.26-2.37) and rs28386840 SLC6A2 (odds ratio: 2.93; confidence interval: 1.76-4.90), and,

116 saw the movie not containing guns (adjusted odds ratio, 22.3; 95% CI, 6.0-83.4; P < .001).

117 hose in the lowest income quartile (adjusted odds ratio, 3.04; 95% CI, 2.53-3.66).

118 -en-Y hepaticojejunostomy (vs duct-to-duct) (odds ratio, 3.06; 95% confidence interval, 1.52-6.16; P

119 6-9.7) and a family history of sudden death (odds ratio, 3.2; 95% confidence interval, 1.1-9.4) were

120 ST compared with patients treated with EES (odds ratio, 3.33; 95% confidence interval, 1.97-5.62; P<

121 1), need for left ventricular assist device (odds ratio, 3.48; 95% confidence interval, 2.25-5.36; P<

122 decrease in eGFR of >1 ml/min per 1.73 m(2) (odds ratio, 3.64; 95% confidence interval, 1.37 to 9.91)

123 as significantly higher in the CAV(+) group (odds ratio, 3.9; P=0.0317) than in the CAV(-) group.

124 associated with a pattern of stable housing (odds ratio = 4.4, 95% confidence interval: 2.9, 6.8), an

125 Prior syncope (odds ratio, 4.0; 95% confidence interval, 1.6-9.7) and a

126 ility of nevus dermoscopic pattern (adjusted odds ratio, 4.24; 95% CI, 1.36-13.25; P = .01) were asso

127 of 283 [31.4%] vs 26 of 282 [9.2%]; adjusted odds ratio, 4.6; 95% CI, 1.5-14.7) and a greater proport

128 analysis, multidrug-resistant A. baumannii (odds ratio, 4.78; 95% CI, 2.14-18.45) and specific healt

129 ith non-CP-CRE bacteremic patients (adjusted odds ratio, 4.92; 95% confidence interval, 1.01-24.81).

130 ) of 170 in the historical comparison group (odds ratio: 4.0; 95% confidence interval: 2.08 to 7.7; p

131 = 9.52; P = 0.001), and high-dose steroids (odds ratio = 5.05; P = 0.01) retained significance in mu

132 h the endotracheal tube or tracheotomy site [odds ratio, 5.15; 95% CI, 2.10-12.60]), were associated

133 associated with a CAC score greater than 0 (odds ratio, 5.1; 95% CI, 4.1-6.3; P < .001).

134 x; intravenous iron use for anemia (adjusted odds ratio, 5.4 [95% confidence interval, 1.4-21.1]); ma

135 95% confidence interval, 4.7-55.9) and COPD (odds ratio, 5.76; 95% confidence interval, 1.9-17.4), bu

136 severe acute respiratory infection (adjusted odds ratio, 5.87; 95% CI, 4.02-8.56; p < 0.001).

137 d 17% of controls had an ICD recommendation (odds ratio, 5.9; P<0.001).

138 incident nonmedical prescription opioid use (odds ratio=5.78, 95% CI=4.23-7.90) and opioid use disord

139 of in-hospital death were cardiogenic shock (odds ratio, 6.01; 95% confidence interval, 4.19-8.61; P<

140 and HRP prevalence beyond traditional risk (odds ratio, 6.0; 95% confidence interval, 1.1-31.7; P=0.

141 1-point decrease in mRS score at discharge (odds ratio, 6.4; 95% CI, 1.7-23.4; P = .005).

142 ciated with an eGFR<60 ml/min per 1.73 m(2) (odds ratio, 6.85; 95% confidence interval, 1.34 to 46.20

143 en similarly depressed at baseline (adjusted odds ratio 7.38, 1.73-31.50; p=0.0069).

144 entral nervous system (CNS) synucleinopathy (odds ratio = 7.1).

145 , 95% CI=4.23-7.90) and opioid use disorder (odds ratio=7.76, 95% CI=4.95-12.16) at wave 2.

146 CI, 1.00-4.82], performing a wound dressing [odds ratio, 8.35; 95% CI, 2.07-33.63] and interacting wi

147 Rituximab (odds ratio = 9.52; P = 0.001), and high-dose steroids (o

148 alysis, baseline total nevus count (adjusted odds ratio, 9.08; 95% CI, 4.0-23.7; P < .001) and increa

149 ignificant increase in their late TTA group (odds ratio, 9.63; 95% CI, 1.08-86.17; P = .03).

150 ple, greater grip strength (per 6 kg) had an odds ratio (95% CI) of 0.85 (0.73-1.00) for inpatient ad

151 odds of vitamin D deficiency (</=20 ng/mL) [odds ratio (95% CI): 1.19 (1.06, 1.35) for molar sum of

152 independently associated with incident CVD (odds ratio [95% confidence interval]: 1.52 [1.07-2.16])

153 c orders had a greater odds of milk allergy (Odds Ratio; 95% Confidence interval) (1.78; 1.28-2.48),

154 10% was strongly associated with infections (odds ratio, 99).

155 We estimated odds ratios and 95% confidence intervals for asthma usin

156 yses were conducted for individual variants; odds ratios and 95% confidence intervals for the risk of

157 Crude and adjusted odds ratios and corresponding 95% CIs were estimated for

158 ] of 86 participants, respectively, adjusted odds ratio [aOR] 0.46, 95% CI 0.23-0.89; p=0.02).

159 risk HPV than did those not on ART (adjusted odds ratio [aOR] 0.83, 95% CI 0.70-0.99; I(2)=51%, adjus

160 illin or cephalosporin use overall (adjusted odds ratio [aOR] 1.3; 95% CI, 0.8-2.0), we observed sign

161 Both CT HU (adjusted odds ratio [AOR] = 0.9989, interquartile odds ratio [IOR

162 y associated with renal impairment (adjusted odds ratio [aOR] = 2.1; 95% confidence interval [CI] = 1

163 attained minimum dietary diversity (adjusted odds ratio [aOR] for women 1.39, 95% CI 1.03-1.90; for c

164 Exposure to Alternaria (adjusted odds ratio [aOR], 1.07; 95% CI, 1.03-1.11), Leptosphaeri

165 reater odds of unfavorable outcome (adjusted odds ratio [aOR], 1.44; 95% CI, 1.24-1.66) compared with

166 se with resolved or current asthma (adjusted odds ratio [aOR], 1.9 [95% CI, 1.1-1.3] and 1.7 [95% CI,

167 h recent antecedent antibiotic use (adjusted odds ratio [aOR], 4.17; 95% confidence interval [CI], 1.

168 th among patients aged 18-49 years (adjusted odds ratios [aOR] = 0.21; 95% confidence interval [CI],

169 Adjusted odds ratios (AORs) and 95% CIs were calculated.

170 del was constructed to quantify the adjusted odds ratios (aORs) of the exposure to PM10 and the risks

171 ity was associated with unfavorable outcome (odds ratio %cerebral perfusion pressure < lower limit of

172 n the siblings of affected male individuals (odds ratio [confidence interval] = 1.14 [1.11-1.18], p =

173 both in patients who had GA (adjusted common odds ratio (cOR) 1.52, 95% CI 1.09-2.11, p=0.014) and in

174 ir natural log-transformed effect estimates (odds ratios) extracted from genome-wide association stud

175 ortality occurred after perforation, with an odds ratio for 12-month mortality of 1.35 for perforatio

176 erforation on mortality was evident, with an odds ratio for 12-month mortality of 1.60 for perforatio

177 or forest service employees and hunters, the odds ratio for alpha-gal-sIgE positivity was 2.48 compar

178 n with smoking status was stronger in women (odds ratio for ex-smokers [ORex], 1.44; ORcurrent, 3.45)

179 ncidence of CKD in the fully adjusted model (odds ratio for fourth versus first quartile, 1.81; 95% c

180 f MAC use in the VHA increased 17% per year (odds ratio for increase, 1.17; 95% confidence interval,

181 month modified Rankin Scale scores: adjusted odds ratio for the fifth quintile versus first quintile,

182 The odds ratios for being PCR positive was 7.4 (95% confiden

183 The adjusted odds ratios for gastroschisis for a 4-point increase in

184 We estimated multivariable odds ratios for mortality and postnatal HIV transmission

185 al health problems at baseline and estimated odds ratios for subsequent onset of maternal and child m

186 There were no significant differences in the odds ratios for treatment retention (1.32; 95% CI, 0.87-

187 ted odds ratio [AOR] = 0.9989, interquartile odds ratio [IOR] = 0.4206) and BV/TV (AOR= 0.8096, IOR =

188 ast cancer risk overall (interquartile range odds ratio [IQ-OR], 1.37; 95% CI, 1.14 to 1.66; mC, 0.55

189 Second, the median odds ratio (MOR) was calculated to quantify heterogeneit

190 Metrics of heterogeneity, including median odds ratio (MOR), were calculated.

191 ore was calculated by the natural log of the odds ratio multiplied by the number of risk alleles.

192 ined statistically significant with adjusted odds ratio of 0.65 (95% CI, 0.49-0.87) for any rejection

193 ospitals in any study year, with an adjusted odds ratio of 1.13 (0.77-1.65) in 2001, 0.99 (0.77-1.27)

194 in ICU admission, corresponding to a median odds ratio of 2.3, compared to 25.8% (95% CI, 24.5-27.1%

195 : 71%, 80%), respectively, with a diagnostic odds ratio of 8 (95% CI: 3, 18) and only fair interobser

196 Based on four SNPs, the odds ratio of AD per genetically predicted one standard

197 previous cesarean deliveries, with adjusted odds ratios of 1.16 (95% CI, 0.98-1.37) for 1 cesarean d

198 The odds ratios of complicated appendicitis for late vs earl

199 f 0.94, specificity of 0.71 and a diagnostic odds-ratio of 36.8.

200 e), only 1 (7.7%) eye developed new vessels, odds ratio (OR) 0.12 [95% confidence interval (CI): 0.01

201 t difference in postoperative complications [odds ratio (OR) 0.91; 95% confidence interval (CI) 0.81,

202 anastomosis was associated with 30-day POM [odds ratio (OR) 1.71; 95% confidence interval (CI) 1.05-

203 % increased odds of improving SMR over time [odds ratio (OR) 1.73; 95% confidence interval (CI) 1.03-

204 r the intravenous group than the oral group [odds ratio (OR) 1.74, 95% confidence interval (CI) 1.05-

205 the highest quartile (4th) vs. lowest (1st), odds ratio (OR) = 0.66, 95% confidence interval (CI): 0.

206 s inversely associated with the odds of EOC (odds ratio (OR) = 0.75, 95% confidence interval (CI): 0.

207 ren according to prenatal exposure to fever (odds ratio (OR) = 1.01, 95% confidence interval (CI): 1.

208 lelic frequency = 0.026%, P = 4.0 x 10(-12), odds ratio (OR) = 16.7) and a frameshift mutation, rs532

209 ers (for fourth quartile vs. first quartile, odds ratio (OR) = 2.70, 95% confidence interval (CI): 1.

210 pecies (ROS) production, predisposes to SLE (odds ratio (OR) = 3.47 in Asians (Pmeta = 3.1 x 10(-104)

211 es making individual comparisons we used the odds ratio (OR) and corresponding 95% CIs as the primary

212 Odds ratio (OR) assessment for AID-directed therapies.

213 The overall odds ratio (OR) for ER visits for GI illness was 1.09 [9

214 Odds ratio (OR) for predicting poor outcome or standardi

215 ully-adjusted logistic regression model, the odds ratio (OR) per 10 unit change in renal elasticity f

216 onfidence interval: 1.12-2.55), rs4680 COMT (odds ratio (OR): 1.40; confidence interval: 1.04-1.87),

217 ng protein 15; rs4662344-T: P=1.9 x 10(-18), odds ratio (OR)=1.23) and COLQ (collagen-like tail subun

218 dicted PTSD after subsequent random traumas (odds ratio (OR)=1.3-2.5).

219 pared with individuals who did not have ASD (odds ratio (OR)=22.33, 95% confidence interval (CI): 21.

220 n increased risk of bladder cancer [adjusted odds ratios (OR) = 3.90, 95% confidence interval (CI) =

221 Odds ratios (OR) and 95% confidence intervals (CI) were

222 ldren with higher than lower estradiol, with odds ratios (OR) for asthma ranging from 1.25 for PFOS (

223 The odds ratios (OR) of the prevalence of asymptomatic ICAS

224 ated with a decreased alloimmunization risk (odds ratio [OR] 0.26, 95% confidence [CI] 0.11-0.64).

225 ess often parasitemic compared to AA adults (odds ratio [OR] 0.50 95% confidence interval [CI] 0.31-0

226 primary outcome were short disease duration (odds ratio [OR] 0.64, 95% CI 0.41-0.997 per year; p=0.04

227 wns dominated by domestic private ownership (odds ratio [OR] 0.74, 95% CI 0.61-0.90) or by foreign in

228 ) included longer total duration of uveitis (odds ratio [OR] 1.13, P < .001), bilateral uveitis (OR 3

229 ntion clusters than in the control clusters (odds ratio [OR] 1.31, 95% CI 1.11-1.53).

230 roving adherence in both the global network (odds ratio [OR] 1.48, 95% credible interval [CrI] 1.00-2

231 reased tuberculosis diagnosis by microscopy (odds ratio [OR] 1.6, 95% CI 1.3-1.9, p<0.0001) or cultur

232 combined minor allele frequency [MAF] 0.22%; odds ratio [OR] 2.02; 95% CI 0.73-5.60; P = 0.18).

233 e blood pressure-lowering medicine (adjusted odds ratio [OR] 2.23, 95% CI 1.59-3.12); p<0.0001), comb

234 , 2.2% [1 of 45] vs no-LD, 26.2% [11 of 42]; odds ratio [OR] = 0.062; confidence interval [CI], 0.011

235 rative or postoperative complication by 80% (odds ratio [OR] = 0.2, 95% confidence interval [CI] = 0.

236 pendicitis were longer duration of symptoms (odds ratio [OR] = 1.46, P < .0001), increased maximum di

237 eased the odds of ONHD presence by 1.5-fold (odds ratio [OR] = 1.56 [confidence interval (CI), 1.22-2

238 ecurely attached to their primary caregiver (odds ratio [OR] = 1.7, p = 0.029, 95% CI [1.06, 2.76], d

239 redictive value were coma (31% had seizures; odds ratio [OR] = 1.8, p < 0.01) and history of seizures

240 s were less likely to report skin clearance (odds ratio [OR], 0.20; 95% CI, 0.07-0.55) and more likel

241 kely to experience prolonged length of stay (odds ratio [OR], 0.50; 95% CI, 0.26-0.97; P = .04), more

242 ith reductions in injurious falls: exercise (odds ratio [OR], 0.51 [95% CI, 0.33 to 0.79]; absolute r

243 likely to be adherent in both the tamoxifen (odds ratio [OR], 0.57; 95% CI, 0.37 to 0.86; P = .007) a

244 showed that isoniazid regimens of 6 months (odds ratio [OR], 0.65 [95% credible interval {CrI}, 0.50

245 nt antibiotics had lower 30-day ACS-related (odds ratio [OR], 0.71; 95% CI, 0.50-1.00) and all-cause

246 endently associated with lower maternal age (odds ratio [OR], 0.87; 95% CI, 0.78-0.94), primiparity (

247 etween TRT and overall prostate cancer risk (odds ratio [OR], 1.03; 95% CI, 0.90 to 1.17).

248 re was independently associated with cancer (odds ratio [OR], 1.08 per procedure; 95% CI, 1.04-1.13).

249 ose with DR were more likely to have fallen (odds ratio [OR], 1.31; 95% CI, 1.07-1.60; P = .008) comp

250 44 times higher per 10-year increase in age (odds ratio [OR], 1.44; 95% confidence interval [CI], 1.2

251 with firearm violence in the validation set (odds ratio [OR], 1.47 [95% CI, 1.23 to 1.79]); this asso

252 ared with unexposed offspring (preterm birth odds ratio [OR], 1.47 [95% CI, 1.40-1.55]; small for ges

253 d with higher NAFLD activity score (adjusted odds ratio [OR], 1.644; P = 0.021), whereas elevated cre

254 non-Indigenous Australians, increasing age (odds ratio [OR], 1.72 per decade) and having not had an

255 al FS at 1 year post-HT: >/=18 years of age (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-

256 The presence of subretinal fluid (odds ratio [OR], 1.98; 95% confidence interval [CI], 1.2

257 se who had more limited screening initially (odds ratio [OR], 2.0 [CI, 1.2 to 3.4]) but not at 12 mon

258 are-for their general preventive care (black odds ratio [OR], 2.01; 95% CI, 1.43 to 2.82; Asian OR, 1

259 n midlife was associated with elevated SUVR (odds ratio [OR], 2.06; 95% CI, 1.16-3.65).

260 nonsignificant impact on hospital mortality (odds ratio [OR], 2.1; P = 0.1; OR, 5, P = 0.05, respecti

261 Asthma was solely associated with pattern 1 (odds ratio [OR], 3.3; 95% CI, 1.5-7.2), rhinitis with pa

262 ent eGFR improvement were the LdT treatment (odds ratio [OR], 3.97 (1.37-11.5), p = 0.01) and pre-tre

263 Parathyroid lesion size of 10 mm or less (odds ratio [OR], 4.37; 95% CI, 2.24-8.54), multigland di

264 ntly increased among first-degree relatives (odds ratio [OR], 7.19; 95% CI, 5.65-9.14), particularly

265 Ischemic heart disease (odds ratio [OR], 7.21; P < 0.001) and greater age (OR, 1

266 ations compared to non-use (14.3% vs. 33.3%; odds ratio [OR]: 0.33, 95% confidence interval [CI]: 0.1

267 %) with RA and 712 patients (17.4%) with FA (odds ratio [OR]: 0.87; 95% confidence interval [CI]: 0.7

268 sociated negatively with cumulative smoking (odds ratio [OR]: 0.992; 95% CI 0.984-1.000 per pack-year

269 d severe periodontitis in the entire sample (odds ratio [OR]: 1.7, 95% confidence interval [CI]: 1.3

270 of incident back pain among female subjects (odds ratio [OR]: 1.75, 95% confidence interval [CI]: 1.0

271 nificantly protect against clinical malaria (odds ratio [OR]=0.95, 95% CI 0.68-1.32, p=0.745 for case

272 th a positive organizational safety climate (Odds Ratio [OR]=2.76, 95% Confidence Interval [CI] 1.51-

273 ions in 30-day and 90-day mortality from EP (odds ratio, OR 0.51, 95% confidence interval, CI, 0.40-0

274 data were more likely to be female (adjusted odds ratio (ORadj) = 3.1; 95% confidence interval (CI) 2

275 tatus (single or multiple primary melanoma); odds ratios (ORs) and 95% CIs are reported.

276 We estimated odds ratios (ORs) and 95% confidence intervals (CIs) by

277 We calculated odds ratios (ORs) and 95% confidence intervals (CIs) usi

278 ssion analysis was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs).

279 istic regression was used to obtain adjusted odds ratios (ORs) and adjusted rate differences with 95%

280 implant and patient level to obtain adjusted odds ratios (ORs) and to control possible confounding ef

281 ere pooled in meta-analyses and expressed as odds ratios (ORs) or beta-estimates with 95% confidence

282 stic regression models were used to estimate odds ratios (ORs) that were adjusted for comorbidity, ed

283 We calculated pooled odds ratios (ORs) using a random-effects model.

284 of dynamic contrast-enhanced (DCE) imaging, odds ratios (ORs) were calculated as the ratio of odds o

285 Adjusted odds ratios (ORs) were calculated for each cohort and in

286 Effect sizes were reported as odds ratios (ORs) with 95% CIs.

287 Odds ratios (ORs) with 95% confidence intervals (CIs) fo

288 ho had not (n=1536): for social disadvantage odds ratios [ORs] ranged from 1.34 (95% CI 1.25-1.43) fo

289 oss compared with bevacizumab only (1.25 log odds ratio; P < 0.0016).

290 irst-trimester average atmospheric pressure (odds ratio per 5-mbar increase = 1.06, 95% confidence in

291 increased risk of borderline tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval (CI): 1

292 epinephrine as initial vasopressor (adjusted odds ratio quartile 4 vs quartile 1, 2.1; 95% CI, 1.6-2.

293 re likely to have lactate measured (adjusted odds ratio quartile 4 vs quartile 1, 2.8; 95% CI, 2.1-3.

294 ated and subsequently combined into a pooled odds ratio using a random-effects model.

295 rs) to those who were not regular users, the odds ratio was 2.0 (95% confidence interval: 1.2, 3.4).

296 of sensitivity, specificity, and diagnostic odds ratio were calculated.

297 Odds ratios were calculated for OSs, and periodontal par

298 Adjusted odds ratios were calculated using multivariable logistic

299 Study-specific odds ratios were estimated and subsequently combined int

300 tion of men to the analysis yielded the same odds ratios when correctly adjusting for confounding.